Pills, Shocks and Jabs


Book Description




New Treatments for Addiction


Book Description

New and improved therapies to treat and protect against drug dependence and abuse are urgently needed. In the United States alone about 50 million people regularly smoke tobacco and another 5 million are addicted to other drugs. In a given year, millions of these individuals attemptâ€"with or without medical assistanceâ€"to quit using drugs, though relapse remains the norm. Furthermore, each year several million teenagers start smoking and nearly as many take illicit drugs for the first time. Research is advancing on promising new means of treating drug addiction using immunotherapies and sustained-release (depot) medications. The aim of this research is to develop medications that can block or significantly attenuate the psychoactive effects of such drugs as cocaine, nicotine, heroin, phencyclidine, and methamphetamine for weeks or months at a time. This represents a fundamentally new therapeutic approach that shows promise for treating drug addiction problems that were difficult to treat in the past. Despite their potential benefits, however, several characteristics of these new methods pose distinct behavioral, ethical, legal, and social challenges that require careful scrutiny. Such issues can be considered unique aspects of safety and efficacy that are fundamentally related to the distinct nature and properties of these new types of medications.




Administered Prices


Book Description







Happy Pills in America


Book Description

Valium. Paxil. Prozac. Prescribed by the millions each year, these medications have been hailed as wonder drugs and vilified as numbing and addictive crutches. Where did this “blockbuster drug” phenomenon come from? What factors led to the mass acceptance of tranquilizers and antidepressants? And how has their widespread use affected American culture? David Herzberg addresses these questions by tracing the rise of psychiatric medicines, from Miltown in the 1950s to Valium in the 1970s to Prozac in the 1990s. The result is more than a story of doctors and patients. From bare-knuckled marketing campaigns to political activism by feminists and antidrug warriors, the fate of psychopharmacology has been intimately wrapped up in the broader currents of modern American history. Beginning with the emergence of a medical marketplace for psychoactive drugs in the postwar consumer culture, Herzberg traces how “happy pills” became embroiled in Cold War gender battles and the explosive politics of the “war against drugs”—and how feminists brought the two issues together in a dramatic campaign against Valium addiction in the 1970s. A final look at antidepressants shows that even the Prozac phenomenon owed as much to commerce and culture as to scientific wizardry. With a barrage of “ask your doctor about” advertisements competing for attention with shocking news of drug company malfeasance, Happy Pills is an invaluable look at how the commercialization of medicine has transformed American culture since the end of World War II.




Competitive problems in the drug industry


Book Description




Competitive Problems in the Drug Industry


Book Description




68W Advanced Field Craft


Book Description

The Combat Medic of today is the most technically advanced ever produced by the United States Army. Such an advanced technician requires an advanced teaching and learning system. 68W Advanced Field Craft is the first textbook designed to prepare the Combat Medic for today's challenges in the field. The ability to save lives in war, conflicts, and humanitarian inventions requires a specific skill set. Today's Combat Medic must be an expert in emergency medical care, force health protection, limited primary care, evacuation, and warrior skills. 68W Advanced Field Craft combines complete medical content with dynamic features to support instructors and to prepare Combat Medics for their missions.




Vaccines, Medicines and COVID-19


Book Description

This open access book is a collection of research papers on COVID-19 by Germán Velásquez from 2020 and early 2021 that help to answer the question: How can an agency like the World Health Organization (WHO) be given a stronger voice to exercise authority and leadership? The considerable health, economic and social challenges that the world faced at the beginning of 2020 with COVID-19 continued and worsened in many parts of the world in the second-half of 2020 and into 2021. Many of these countries and nations wanted to explore COVID-19 on their own, sometimes without listening to the main international health bodies such as WHO, an agency of the United Nations system with long-standing experience and vast knowledge at the global level and of which all countries in the world are members. In this single volume, the chapters present the progress of thinking and debate — particularly in relation to drugs and vaccines — that would enable a response to the COVID-19 pandemic or to subsequent crises that may arise. Among the topics covered: COVID-19 Vaccines: Between Ethics, Health and Economics Medicines and Intellectual Property: 10 Years of the WHO Global Strategy Re-thinking Global and Local Manufacturing of Medical Products After COVID-19 Rethinking R&D for Pharmaceutical Products After the Novel Coronavirus COVID-19 Shock Intellectual Property and Access to Medicines and Vaccines The World Health Organization Reforms in the Time of COVID-19 Vaccines, Medicines and COVID-19: How Can WHO Be Given a Stronger Voice? is essential reading for negotiators from the 194 member countries of the World Health Organization (WHO); World Trade Organization (WTO) and World Intellectual Property Organization (WIPO) staff participating in these negotiations; academics and students of public health, medicine, health sciences, law, sociology and political science; and intergovernmental organizations and non-governmental organizations that follow the issue of access to treatments and vaccines for COVID-19.




Prescribed Medications and the Public Health


Book Description

An alarming look at America’s other drug problem—medication safety! Drug misadventures are an all-too-frequent and deadly cause of adverse medical events. Prescribed Medications and the Public Health: Laying the Foundation for Risk Reduction explores ways to combat the widespread problem of adverse drug events (ADEs). This comprehensive book shows how our broken health care and medication use system often inflicts harm—most of it preventable—on patients. Strategies are presented to help health care managers, health professionals, regulators, and policymakers to dynamically improve the entire system. With the growing use of prescribed medications comes a rising number of adverse drug reactions, drug interactions, allergic reactions, and medication errors. Prescribed Medications and the Public Health discusses problems such as drug supply issues, drug defects, counterfeit drugs, limitations for oversight of Internet prescriptions, inaccurate splitting of pills, and poor administration of drugs. The book examines the issues from all angles, including patient considerations, drug factors, and unsafe practices that contribute to ADEs. Liability costs for drug injury are reviewed, along with effective practical strategies for preventing, reducing, detecting, and documenting adverse drug events. National and local plans are explored to help achieve the essential goal of greater safety throughout the system. The text is extensively referenced and includes approximately 50 figures and tables to clearly present information. Prescribed Medications and the Public Health reviews in detail how to battle these problems in both inpatient and ambulatory care: adverse drug reactions dangerous allergic reactions harmful drug interactions medication errors adverse vaccine reactions drug misadventures Prescribed Medications and the Public Health is crucial reading for medication safety officers; pharmacoepidemiologists; medication safety experts; educators and students in schools of pharmacy and public health, medicine, nursing, and hospital/health services management; health care managers; regulators; policymakers; and advocates for improving drug safety.